 H.C. Wainwright has lowered TG Therapeutics Incs NASDAQ:TGTX price target to 84 from 89 and keeps a Buy rating on the stock. Analyst Edward White mentioned that Ukoniq umbralisib revenue of 1.5 million was lower than expected in Q2. 